184475-35-2 Gefitinib AKSci J10250
 
 
Loading Please Wait...
  J10250    
Gefitinib
, >98% (HPLC)
 
Iressa
Irressat
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine




IDENTITY
CAS Number:184475-35-2
MDL Number:MFCD04307832
MF:C22H24ClFN4O3
MW:446.9
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:NMR, LCMS, HPLC
Physical Form:White to off-white crystalline powder or powder
Melting Point:188-198°C
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO: 89mg/mL; H2O: <1mg/mL; EtOH: 4mg/mL
Application(s):Orally active, selective EGFR inhibitor
Form:Free Base

REVIEW

 Gefitinib is the first selective inhibitor of epidermal growth factor receptor''s (EGFR) tyrosine kinase domain. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways. These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.

REFERENCES
[1]Pao W, Miller V, Zakowski M, et al. (September 2004). EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America 101 (36): 13306-11. doi:10.1073/pnas.0405220101. PMC 516528. PMID 15329413.
[2] Sordella R, Bell DW, Haber DA, Settleman J (August 2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (5687): 1163-7. doi:10.1126/science.1101637. PMID 15284455.
[3] Takimoto CH, Calvo E. Principles of Oncologic Pharmacotherapy in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
[4] Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009; 361. 10.1056/NEJMoa0810699.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of January 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem